Medigene: Transition To Prominent Immunotherapy Player – Investing.com
|
Medigene: Transition To Prominent Immunotherapy Player
Investing.com Medigene's (DE:MDG1k) H1 results are in line with our expectations and represent the completion of its transformation into a prominent T-cell immunotherapy player. Highlights from H1 include submission of a clinical trial authorisation (CTA) to begin … |
